Atopic Dermatitis (AD) is a T cell hypersensitivity skin disease and is associated with weakened skin barrier. People with mutations in genes involved in tissue barrier fitness are predisposed towards inflammatory diseases, but most susceptible individuals do not develop the diseases, suggesting that there exist regulatory immune mechanisms. We have developed an animal model to identify the regulatory immune circuit that prevents AD. Absence of innate IL-17+ ?? T (T??17) cells results in spontaneous AD with all major hallmarks of human AD, placing these cells as the apex regulator of skin homeostasis. In the chronic AD stage, distinct CD4+ T helper effector subsets of constrained clonotypes dominate. Skin Th17 and Th22 cells are commensal bacteria (CB)- dependent, highly restricted in T cell antigen receptor (TCR) repertoire, and some of the clonotypes are extensively expanded in normal and diseased skin. Coincidently, type 2 cytokine secreting innate lymphoid cells 2 (ILC2) expand, which sets up an amplifying autofeedback loop with T cells to chronically inflame the skin. The following model of AD progression will be tested: 1. Regulatory stage: Dermal T??17 cells and ?? T cells survey skin homeostasis and barrier integrity by monitoring dermal APCs. T??17 and Th2 cells seed the skin early in life. T??17 cells, CB and local DCs coordinately promote barrier integrity through crosstalk with keratinocytes. Meanwhile, polyclonal Th2 cells are positioned to induce an allergic response towards invading pathogens. During the colonization of skin by CB, a symbiotic immune response ensues with V?4+ CB-specific CD4+ T cells expanding and differentiating into `non-pathogenic' skin resident IL-17+ T cells. 2. Elicitation stage: When T??17 cells are compromised, the barrier is degraded over time with an attendant leakage of CB and enhanced necroptosis, leading to the release of skin antigens that activate Th2 cells, and DAMPs, the most critical being IL-33. In conjunction with TSLP released by keratinocyte under stress, IL-33 drives ILC2 expansion, which further amplifies Th2 cells. Activated ILC2 and Th2 cells, in turn unleash mast cells. Together, excess type 2 cytokine production recruits eosinophils. Some tissue-resident, Th17 cells become activated and promote neutrophil recruitment. 3. Pathogenic stage: During the acute phase, IL-17 release further recruits neutrophils and amplifies the inflammatory cascade that leads to epithelial barrier damage. Inflammation and antigen release from damaged skin activates oligoclonal T cells in the skin dLNs and/or in lesional skin sites. IL-1, IL-6, IL-23, Ahr ligands and TNF? released during inflammation induces skin-resident Th17 cells to expand and acquire a `pathogenic' dual IL-17/22+ phenotypes, whereas the emergent Th22 cells represent an immune countermeasure to repair damaged skin. By mapping central cellular interactions and molecular regulatory network in spontaneous mouse models of AD, the origin of AD and the nature of pathogenic T cells can be understood, paving the way towards identification of T cell skin antigens responsible for AD.

Public Health Relevance

Atopic dermatitis (AD) is a chronic, relapsing skin disorder involving impaired skin barrier integrity and excessive type 2 cytokine responses. Among children of developed countries, as many as a quarter of them can be impacted by this disease. Despite major progress in mapping AD-associated genetic and immune cell alterations, the disease-triggering events and identity of disease causing self-reactive T cell clones remain uncertain. We have discovered that innate T lymphocytes resident in the skin are the apex regulators of skin homeostasis. Further, we have identified candidate T cell clones that cause the disease. This project will systematically map the sequence of events mediated by skin lymphocytes from the initiation to chronic phase of AD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
1R01AR071269-01A1
Application #
9332774
Study Section
Cellular and Molecular Immunology - A Study Section (CMIA)
Program Officer
Cibotti, Ricardo
Project Start
2017-04-01
Project End
2022-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
1
Fiscal Year
2017
Total Cost
$583,121
Indirect Cost
$234,989
Name
University of Massachusetts Medical School Worcester
Department
Pathology
Type
Schools of Medicine
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Spidale, Nicholas A; Sylvia, Katelyn; Narayan, Kavitha et al. (2018) Interleukin-17-Producing ?? T Cells Originate from SOX13+ Progenitors that Are Independent of ??TCR Signaling. Immunity 49:857-872.e5
Rowe, Jared H; Stadinski, Brian D; Henderson, Lauren A et al. (2017) Abnormalities of T-cell receptor repertoire in CD4+ regulatory and conventional T cells in patients with RAG mutations: Implications for autoimmunity. J Allergy Clin Immunol 140:1739-1743.e7